Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine in Alcohol Relapse Prevention
NCT00561587Phase 2Completed
- Sponsor
- Institut für anwendungsorientierte Forschung und klinische Studien
- Start
- Nov 2007
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of quetiapine (extended-release tablet, brand name: Bipresso) in alcohol dependence, sponsored by Institut für anwendungsorientierte Forschung und klinische Studien. Primary endpoint: Alcohol Relapse at 7 months. Started Nov 2007; status: completed.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
alcohol dependence
Beyond the preview
Go deeper on NCT00561587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00561587.